https://pubmed.ncbi.nlm.nih.gov/33216133/

2020 Nov 20;jiaa719.

doi: 10.1093/infdis/jiaa719. Online ahead of print.

Genetic background amplifies the effect of immunodeficiency in antibiotic efficacy against Borrelia burgdorferi

PMID: 33216133

DOI: 10.1093/infdis/jiaa719

Abstract

Unrecognized immunodeficiency has been proposed as a possible cause of failure of antibiotics to resolve symptoms of Lyme disease. Here, we examined the efficacy of doxycycline in different immune deficient mice to identify defects that impair antibiotic treatment outcomes. We found that doxycycline had significantly lower efficacy in the absence of adaptive immunity, specifically B cells. This effect was most pronounced in immunodeficientC3H mice compared with C57BL/6 mice suggesting a role for genetic background beyond immunodeficiency.

Addition of a single dose of ceftriaxone to doxycycline treatment effectively cleared infection in C3H mice with severe combined immunodeficiency.

____________________

**Comment**

Since mainstream medicine under the tutelage of the CDC and IDSA believes Lyme literate doctors are charlatans, they have closed minds and refuse to even consider what LLMD’s have found success with. LLMD’s have known for decades that the mono therapy of doxycycline is ineffective in treating Lyme/MSIDS – for anything other than acute cases, with antibiotic failures experienced in nearly every single study done – as well as clinically.  LLMD’s layer treatment.  Please see:

While the immune system is an important factor with tick-borne illness, many patients are infected with numerous pathogens making their cases far more complex than main stream medicine admits to.  What scant research exists on this topic shows polymicrobial illness makes cases far more complex & serious, necessitating longer treatment utilizing many antimicrobials layered together to work synergistically.  LLMD’s support the immune system, realize the importance of antimicrobials, and focus on detoxification.  It’s a multi-pronged approach.